Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 92 entries
Sorted by: Best Match Show Resources per page
Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report.

Oncology letters

Ai DL, Li BT, Peng XM, Zhang LZ, Wang JY, Zhao Y, Yang B, Yu Q, Liu CZ, Yang N, Wang HM, Zhou L.
PMID: 26870287
Oncol Lett. 2016 Jan;11(1):798-800. doi: 10.3892/ol.2015.3934. Epub 2015 Nov 17.

Percutaneous ethanol injection is an important localized treatment method for patients presenting with hepatocellular carcinoma (HCC). Among the advantages of percutaneous ethanol injection are its minimal invasiveness, simplicity, low cost and low risk of complications. However, the increasing popularity...

Cite
Ai DL, Li BT, Peng XM, et al. Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report. Oncol Lett. 2015;11(1):798-800doi: 10.3892/ol.2015.3934.
Ai, D. L., Li, B. T., Peng, X. M., Zhang, L. Z., Wang, J. Y., Zhao, Y., Yang, B., Yu, Q., Liu, C. Z., Yang, N., Wang, H. M., & Zhou, L. (2016). Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report. Oncology letters, 11(1), 798-800. https://doi.org/10.3892/ol.2015.3934
Ai, Ding-Lun, et al. "Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report." Oncology letters vol. 11,1 (2016): 798-800. doi: https://doi.org/10.3892/ol.2015.3934
Ai DL, Li BT, Peng XM, Zhang LZ, Wang JY, Zhao Y, Yang B, Yu Q, Liu CZ, Yang N, Wang HM, Zhou L. Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report. Oncol Lett. 2016 Jan;11(1):798-800. doi: 10.3892/ol.2015.3934. Epub 2015 Nov 17. PMID: 26870287; PMCID: PMC4727072.
Copy Download .nbib Format: NLM
Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura.

Experimental and therapeutic medicine

Wu X, Wang L, Sun L, Li T, Ran X.
PMID: 28352325
Exp Ther Med. 2017 Feb;13(2):519-522. doi: 10.3892/etm.2016.3989. Epub 2016 Dec 21.

The aim of the present study was to evaluate the effectiveness and safety of recombinant human interleukin-11 (IL-11) with glucocorticoids for treatment of adult idiopathic thrombocytopenic purpura (ITP) and the regulatory effect on immune mechanisms. A total of 80...

Cite
Wu X, Wang L, Sun L, et al. Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura. Exp Ther Med. 2016;13(2):519-522doi: 10.3892/etm.2016.3989.
Wu, X., Wang, L., Sun, L., Li, T., & Ran, X. (2017). Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura. Experimental and therapeutic medicine, 13(2), 519-522. https://doi.org/10.3892/etm.2016.3989
Wu, Xifeng, et al. "Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura." Experimental and therapeutic medicine vol. 13,2 (2017): 519-522. doi: https://doi.org/10.3892/etm.2016.3989
Wu X, Wang L, Sun L, Li T, Ran X. Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura. Exp Ther Med. 2017 Feb;13(2):519-522. doi: 10.3892/etm.2016.3989. Epub 2016 Dec 21. PMID: 28352325; PMCID: PMC5347441.
Copy Download .nbib Format: NLM
[Recombinant Human Interleukin 11 (Mega) Promotes Thrombopoiesis in Cancer Patients with Chemotherapy-Induced Myelosuppression].

Zhongguo shi yan xue ye xue za zhi

Chu DT, Xu BH, Song ST, Mao XH, Jiao SC, Zhang AL, Cong J.
PMID: 12578570
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001 Dec;9(4):314-317.

A randomized, selfcross-over and placebo-controlled clinical trial has been taken to evaluated the curative efficacy of rhIL-11 (Mega) for thrombocytopenia in 29 cancer patients with severe myelosuppression induced by chemotherapy. Twenty-five micro g/kg of Mega or placebo was administered...

Cite
Chu DT, Xu BH, Song ST, et al. [Recombinant Human Interleukin 11 (Mega) Promotes Thrombopoiesis in Cancer Patients with Chemotherapy-Induced Myelosuppression]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001;9(4):314-317
Chu, D. T., Xu, B. H., Song, S. T., Mao, X. H., Jiao, S. C., Zhang, A. L., & Cong, J. (2001). [Recombinant Human Interleukin 11 (Mega) Promotes Thrombopoiesis in Cancer Patients with Chemotherapy-Induced Myelosuppression]. Zhongguo shi yan xue ye xue za zhi, 9(4), 314-317.
Chu, Da-Tong, et al. "[Recombinant Human Interleukin 11 (Mega) Promotes Thrombopoiesis in Cancer Patients with Chemotherapy-Induced Myelosuppression]." Zhongguo shi yan xue ye xue za zhi vol. 9,4 (2001): 314-317.
Chu DT, Xu BH, Song ST, Mao XH, Jiao SC, Zhang AL, Cong J. [Recombinant Human Interleukin 11 (Mega) Promotes Thrombopoiesis in Cancer Patients with Chemotherapy-Induced Myelosuppression]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2001 Dec;9(4):314-317. Chinese. PMID: 12578570.
Copy Download .nbib Format: NLM
Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Wilde MI, Faulds D.
PMID: 18020592
BioDrugs. 1998 Aug;10(2):159-71. doi: 10.2165/00063030-199810020-00006.

UNLABELLED: Oprelvekin is a recombinant human interleukin-11. Its predominant haemopoietic activity is stimulation of megakaryocytopoiesis. Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of platelet transfusion requirements following myelosuppressive chemotherapy in patients with nonmyeloid malignancies...

Cite
Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998;10(2):159-71doi: 10.2165/00063030-199810020-00006.
Wilde, M. I., & Faulds, D. (1998). Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 10(2), 159-71. https://doi.org/10.2165/00063030-199810020-00006
Wilde, M I, and Faulds, D. "Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 10,2 (1998): 159-71. doi: https://doi.org/10.2165/00063030-199810020-00006
Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71. doi: 10.2165/00063030-199810020-00006. PMID: 18020592.
Copy Download .nbib Format: NLM
Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells.

Frontiers in physiology

Peterson H, Abu Dawud R, Garg A, Wang Y, Vilo J, Xenarios I, Adjaye J.
PMID: 24194720
Front Physiol. 2013 Oct 28;4:303. doi: 10.3389/fphys.2013.00303. eCollection 2013.

Pluripotency in human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) is regulated by three transcription factors-OCT3/4, SOX2, and NANOG. To fully exploit the therapeutic potential of these cells it is essential to have a good mechanistic...

Cite
Peterson H, Abu Dawud R, Garg A, et al. Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells. Front Physiol. 2013;4:303doi: 10.3389/fphys.2013.00303.
Peterson, H., Abu Dawud, R., Garg, A., Wang, Y., Vilo, J., Xenarios, I., & Adjaye, J. (2013). Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells. Frontiers in physiology, 4303. https://doi.org/10.3389/fphys.2013.00303
Peterson, Hedi, et al. "Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells." Frontiers in physiology vol. 4 (2013): 303. doi: https://doi.org/10.3389/fphys.2013.00303
Peterson H, Abu Dawud R, Garg A, Wang Y, Vilo J, Xenarios I, Adjaye J. Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells. Front Physiol. 2013 Oct 28;4:303. doi: 10.3389/fphys.2013.00303. eCollection 2013. PMID: 24194720; PMCID: PMC3809568.
Copy Download .nbib Format: NLM
Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11.

Molecular cancer

Cai WL, Huang WD, Li B, Chen TR, Li ZX, Zhao CL, Li HY, Wu YM, Yan WJ, Xiao JR.
PMID: 32593305
Mol Cancer. 2020 Jun 27;19(1):111. doi: 10.1186/s12943-020-01226-1.

An amendment to this paper has been published and can be accessed via the original article.

Cite
Cai WL, Huang WD, Li B, et al. Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 2020;19(1):111doi: 10.1186/s12943-020-01226-1.
Cai, W. L., Huang, W. D., Li, B., Chen, T. R., Li, Z. X., Zhao, C. L., Li, H. Y., Wu, Y. M., Yan, W. J., & Xiao, J. R. (2020). Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Molecular cancer, 19(1), 111. https://doi.org/10.1186/s12943-020-01226-1
Cai, Wei-Luo, et al. "Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11." Molecular cancer vol. 19,1 (2020): 111. doi: https://doi.org/10.1186/s12943-020-01226-1
Cai WL, Huang WD, Li B, Chen TR, Li ZX, Zhao CL, Li HY, Wu YM, Yan WJ, Xiao JR. Correction to: microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol Cancer. 2020 Jun 27;19(1):111. doi: 10.1186/s12943-020-01226-1. PMID: 32593305; PMCID: PMC7320564.
Copy Download .nbib Format: NLM
A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling.

iScience

Lokau J, Garbers Y, Grötzinger J, Garbers C.
PMID: 34765926
iScience. 2021 Oct 16;24(11):103309. doi: 10.1016/j.isci.2021.103309. eCollection 2021 Nov 19.

Blocking the activity of cytokines is an efficient strategy to combat inflammatory diseases. Interleukin-6 (IL-6) fulfills its pro-inflammatory properties via its soluble receptor (IL-6 trans-signaling). The selective trans-signaling inhibitor olamkicept (sgp130Fc) is currently in clinical development. We have previously...

Cite
Lokau J, Garbers Y, Grötzinger J, et al. A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling. iScience. 2021;24(11):103309doi: 10.1016/j.isci.2021.103309.
Lokau, J., Garbers, Y., Grötzinger, J., & Garbers, C. (2021). A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling. iScience, 24(11), 103309. https://doi.org/10.1016/j.isci.2021.103309
Lokau, Juliane, et al. "A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling." iScience vol. 24,11 (2021): 103309. doi: https://doi.org/10.1016/j.isci.2021.103309
Lokau J, Garbers Y, Grötzinger J, Garbers C. A single aromatic residue in sgp130Fc/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling. iScience. 2021 Oct 16;24(11):103309. doi: 10.1016/j.isci.2021.103309. eCollection 2021 Nov 19. PMID: 34765926; PMCID: PMC8571719.
Copy Download .nbib Format: NLM
Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome.

Biomarkers in cancer

Keskin H, Cadirci K, Demirkazik A, Akbulut H, Yalcin B.
PMID: 31217693
Biomark Cancer. 2019 Jun 10;11:1179299X19854447. doi: 10.1177/1179299X19854447. eCollection 2019.

Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are...

Cite
Keskin H, Cadirci K, Demirkazik A, et al. Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome. Biomark Cancer. 2019;11:1179299X19854447doi: 10.1177/1179299X19854447.
Keskin, H., Cadirci, K., Demirkazik, A., Akbulut, H., & Yalcin, B. (2019). Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome. Biomarkers in cancer, 111179299X19854447. https://doi.org/10.1177/1179299X19854447
Keskin, Havva, et al. "Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome." Biomarkers in cancer vol. 11 (2019): 1179299X19854447. doi: https://doi.org/10.1177/1179299X19854447
Keskin H, Cadirci K, Demirkazik A, Akbulut H, Yalcin B. Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome. Biomark Cancer. 2019 Jun 10;11:1179299X19854447. doi: 10.1177/1179299X19854447. eCollection 2019. PMID: 31217693; PMCID: PMC6558530.
Copy Download .nbib Format: NLM
IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts.

Rheumatology (Oxford, England)

Adami E, Viswanathan S, Widjaja AA, Ng B, Chothani S, Zhihao N, Tan J, Lio PM, George BL, Altunoglu U, Ghosh K, Paleja BS, Schafer S, Reversade B, Albani S, Ling ALH, O'Reilly S, Cook SA.
PMID: 33590875
Rheumatology (Oxford). 2021 Dec 01;60(12):5820-5826. doi: 10.1093/rheumatology/keab168.

OBJECTIVES: Interleukin 11 (IL11) is highly upregulated in skin and lung fibroblasts from patients with systemic sclerosis (SSc). Here we tested whether IL11 is mechanistically linked with activation of human dermal fibroblasts (HDFs) from patients with SSc or controls.METHODS:...

Cite
Adami E, Viswanathan S, Widjaja AA, et al. IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts. Rheumatology (Oxford). 2021;60(12):5820-5826doi: 10.1093/rheumatology/keab168.
Adami, E., Viswanathan, S., Widjaja, A. A., Ng, B., Chothani, S., Zhihao, N., Tan, J., Lio, P. M., George, B. L., Altunoglu, U., Ghosh, K., Paleja, B. S., Schafer, S., Reversade, B., Albani, S., Ling, A. L. H., O'Reilly, S., & Cook, S. A. (2021). IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts. Rheumatology (Oxford, England), 60(12), 5820-5826. https://doi.org/10.1093/rheumatology/keab168
Adami, Eleonora, et al. "IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts." Rheumatology (Oxford, England) vol. 60,12 (2021): 5820-5826. doi: https://doi.org/10.1093/rheumatology/keab168
Adami E, Viswanathan S, Widjaja AA, Ng B, Chothani S, Zhihao N, Tan J, Lio PM, George BL, Altunoglu U, Ghosh K, Paleja BS, Schafer S, Reversade B, Albani S, Ling ALH, O'Reilly S, Cook SA. IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGFβ-mediated activation of dermal fibroblasts. Rheumatology (Oxford). 2021 Dec 01;60(12):5820-5826. doi: 10.1093/rheumatology/keab168. PMID: 33590875; PMCID: PMC8645270.
Copy Download .nbib Format: NLM
STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis.

Gut

Dawson RE, Deswaerte V, West AC, Tang K, West AJ, Balic JJ, Gearing LJ, Saad MI, Yu L, Wu Y, Bhathal PS, Kumar B, Chakrabarti JT, Zavros Y, Oshima H, Klinman DM, Oshima M, Tan P, Jenkins BJ.
PMID: 34489308
Gut. 2021 Sep 06; doi: 10.1136/gutjnl-2020-323916. Epub 2021 Sep 06.

OBJECTIVE: The absent in melanoma 2 (AIM2) cytosolic pattern recognition receptor and DNA sensor promotes the pathogenesis of autoimmune and chronic inflammatory diseases via caspase-1-containing inflammasome complexes. However, the role of AIM2 in cancer is ill-defined.DESIGN: The expression of...

Cite
Dawson RE, Deswaerte V, West AC, et al. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut. 2021;doi: 10.1136/gutjnl-2020-323916.
Dawson, R. E., Deswaerte, V., West, A. C., Tang, K., West, A. J., Balic, J. J., Gearing, L. J., Saad, M. I., Yu, L., Wu, Y., Bhathal, P. S., Kumar, B., Chakrabarti, J. T., Zavros, Y., Oshima, H., Klinman, D. M., Oshima, M., Tan, P., & Jenkins, B. J. (2021). STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut, . https://doi.org/10.1136/gutjnl-2020-323916
Dawson, Ruby E, et al. "STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis." Gut vol. (2021). doi: https://doi.org/10.1136/gutjnl-2020-323916
Dawson RE, Deswaerte V, West AC, Tang K, West AJ, Balic JJ, Gearing LJ, Saad MI, Yu L, Wu Y, Bhathal PS, Kumar B, Chakrabarti JT, Zavros Y, Oshima H, Klinman DM, Oshima M, Tan P, Jenkins BJ. STAT3-mediated upregulation of the AIM2 DNA sensor links innate immunity with cell migration to promote epithelial tumourigenesis. Gut. 2021 Sep 06; doi: 10.1136/gutjnl-2020-323916. Epub 2021 Sep 06. PMID: 34489308.
Copy Download .nbib Format: NLM
Dermal Mesenchymal Stem Cells from Psoriatic Lesions Stimulate HaCaT Cell Proliferation, Differentiation, and Migration via Activating the PI3K/AKT Signaling Pathway.

Dermatology (Basel, Switzerland)

Liang N, Chang W, Peng A, Cao Y, Li J, Wang Y, Jiao J, Zhang K.
PMID: 34175855
Dermatology. 2021 Jun 25;1-9. doi: 10.1159/000515767. Epub 2021 Jun 25.

BACKGROUND: Psoriasis is a chronic inflammatory skin disease characterized by excessive proliferation and abnormal differentiation of keratinocytes. Dermal mesenchymal stem cells (DMSCs) are not only involved in the regeneration of skin tissue, but also can regulate skin microenvironment by...

Cite
Liang N, Chang W, Peng A, et al. Dermal Mesenchymal Stem Cells from Psoriatic Lesions Stimulate HaCaT Cell Proliferation, Differentiation, and Migration via Activating the PI3K/AKT Signaling Pathway. Dermatology. 2021;1-9doi: 10.1159/000515767.
Liang, N., Chang, W., Peng, A., Cao, Y., Li, J., Wang, Y., Jiao, J., & Zhang, K. (2021). Dermal Mesenchymal Stem Cells from Psoriatic Lesions Stimulate HaCaT Cell Proliferation, Differentiation, and Migration via Activating the PI3K/AKT Signaling Pathway. Dermatology (Basel, Switzerland), 1-9. https://doi.org/10.1159/000515767
Liang, Nannan, et al. "Dermal Mesenchymal Stem Cells from Psoriatic Lesions Stimulate HaCaT Cell Proliferation, Differentiation, and Migration via Activating the PI3K/AKT Signaling Pathway." Dermatology (Basel, Switzerland) vol. (2021): 1-9. doi: https://doi.org/10.1159/000515767
Liang N, Chang W, Peng A, Cao Y, Li J, Wang Y, Jiao J, Zhang K. Dermal Mesenchymal Stem Cells from Psoriatic Lesions Stimulate HaCaT Cell Proliferation, Differentiation, and Migration via Activating the PI3K/AKT Signaling Pathway. Dermatology. 2021 Jun 25;1-9. doi: 10.1159/000515767. Epub 2021 Jun 25. PMID: 34175855.
Copy Download .nbib Format: NLM
Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10.

FEBS letters

Lokau J, Garbers C.
PMID: 34778975
FEBS Lett. 2021 Dec;595(24):3072-3082. doi: 10.1002/1873-3468.14230. Epub 2021 Nov 22.

Interleukin-6 (IL-6) and interleukin-11 (IL-11) are two important pleiotropic cytokines, both of which signal through a homodimer of the β-receptor gp130. Specificity is gained through the unique, nonsignaling α-receptors IL-6R and IL-11R. Soluble variants of IL-6R and IL-11R also...

Cite
Lokau J, Garbers C. Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10. FEBS Lett. 2021;595(24):3072-3082doi: 10.1002/1873-3468.14230.
Lokau, J., & Garbers, C. (2021). Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10. FEBS letters, 595(24), 3072-3082. https://doi.org/10.1002/1873-3468.14230
Lokau, Juliane, and Garbers, Christoph. "Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10." FEBS letters vol. 595,24 (2021): 3072-3082. doi: https://doi.org/10.1002/1873-3468.14230
Lokau J, Garbers C. Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10. FEBS Lett. 2021 Dec;595(24):3072-3082. doi: 10.1002/1873-3468.14230. Epub 2021 Nov 22. PMID: 34778975.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 92 entries